1.93 USD
▲+0.12+2.66%
盘后 1.90 +1.22%
2026-08-03
市值
$133.50M
市盈率
—
EPS
-1.50
股息率
—
52 周区间
1.01 – 7.80
成交量
357.17K
Beta
1.88
目标价
10.25
52W 低 1.0152W 高 7.80
价格走势
公司简介
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Bo...